D.E. Shaw & Co
ONCT

D.E. Shaw & Co’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

D.E. Shaw & Co’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,198
Closed -$100K – 5808
2021
Q3 		$100K Buy
+1,198
New +$99.1K ﹤0.01% 4717
2016
Q4 		– Sell
-90
Closed -$99K – 3656
2016
Q3 		$99K Sell
90
-8
-8% -$6.98K ﹤0.01% 3287
2016
Q2 		$76K Hold
98
– – ﹤0.01% 3275
2016
Q1 		$69K Hold
98
– – ﹤0.01% 3313
2015
Q4 		$96K Hold
98
– – ﹤0.01% 3676
2015
Q3 		$104K Buy
98
+24
+32% +$35.1K ﹤0.01% 3607
2015
Q2 		$153K Buy
74
+30
+68% +$42.6K ﹤0.01% 3614
2015
Q1 		$41K Hold
44
– – ﹤0.01% 3563
2014
Q4 		$45K Hold
44
– – ﹤0.01% 3944
2014
Q3 		$45K Sell
44
-14
-24% -$20.6K ﹤0.01% 4027
2014
Q2 		$113K Sell
58
-52
-47% -$103K ﹤0.01% 4073
2014
Q1 		$236K Sell
110
-27
-20% -$67.3K ﹤0.01% 4023
2013
Q4 		$315K Sell
137
-217
-61% -$496K ﹤0.01% 4037
2013
Q3 		$995K Sell
354
-69
-16% -$343K ﹤0.01% 3044
2013
Q2 		$3.91M Buy
+423
New +$3.26M 0.01% 1543

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM

D.E. Shaw & Co's ONCT Position: Q4 2021 in Review

D.E. Shaw & Co sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2021, closing a stake of 1,198 shares — an estimated $100K sold.

D.E. Shaw & Co first reported a position in ONCT in Q2 2013 and held it in 15 quarters. The position peaked at $3.91M in Q2 2013. 82 funds tracked by Wall St. Rank hold ONCT as of Q4 2021.

  • D.E. Shaw & Co reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,198 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $100K.
  • D.E. Shaw & Co first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
  • D.E. Shaw & Co's Oncternal Therapeutics, Inc. Common Stock position peaked at $3.91M in Q2 2013.
  • 82 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.